JP2022525013A5 - - Google Patents

Info

Publication number
JP2022525013A5
JP2022525013A5 JP2021552772A JP2021552772A JP2022525013A5 JP 2022525013 A5 JP2022525013 A5 JP 2022525013A5 JP 2021552772 A JP2021552772 A JP 2021552772A JP 2021552772 A JP2021552772 A JP 2021552772A JP 2022525013 A5 JP2022525013 A5 JP 2022525013A5
Authority
JP
Japan
Prior art keywords
composition according
pharmaceutically acceptable
acceptable salt
active against
additional agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021552772A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525013A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/051878 external-priority patent/WO2020178767A1/en
Publication of JP2022525013A publication Critical patent/JP2022525013A/ja
Publication of JP2022525013A5 publication Critical patent/JP2022525013A5/ja
Ceased legal-status Critical Current

Links

JP2021552772A 2019-03-06 2020-03-04 Hiv療法において有用な化合物 Ceased JP2022525013A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962814316P 2019-03-06 2019-03-06
US62/814,316 2019-03-06
PCT/IB2020/051878 WO2020178767A1 (en) 2019-03-06 2020-03-04 Compounds useful in hiv therapy

Publications (2)

Publication Number Publication Date
JP2022525013A JP2022525013A (ja) 2022-05-11
JP2022525013A5 true JP2022525013A5 (cg-RX-API-DMAC7.html) 2024-07-16

Family

ID=69845479

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021552772A Ceased JP2022525013A (ja) 2019-03-06 2020-03-04 Hiv療法において有用な化合物

Country Status (22)

Country Link
US (4) US12240853B2 (cg-RX-API-DMAC7.html)
EP (1) EP3934760A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022525013A (cg-RX-API-DMAC7.html)
KR (1) KR20210136052A (cg-RX-API-DMAC7.html)
CN (1) CN113811360A (cg-RX-API-DMAC7.html)
AR (1) AR118240A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020231934B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021017604A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132112A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002309A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021012579A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210460A (cg-RX-API-DMAC7.html)
EA (1) EA202192433A1 (cg-RX-API-DMAC7.html)
IL (1) IL285894A (cg-RX-API-DMAC7.html)
MA (1) MA55200A (cg-RX-API-DMAC7.html)
MX (1) MX2021010700A (cg-RX-API-DMAC7.html)
PE (1) PE20212089A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021500034A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109253SA (cg-RX-API-DMAC7.html)
TW (1) TW202102233A (cg-RX-API-DMAC7.html)
WO (1) WO2020178767A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202106096B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL289925B2 (en) 2019-07-27 2026-03-01 Brii Biosciences Inc A derivative of adenosine and a pharmaceutical preparation containing it
MX2022002897A (es) 2019-09-11 2022-05-16 Scripps Research Inst Profarmacos antivirales y formulaciones de los mismos.
IL293566A (en) * 2019-12-09 2022-08-01 Viiv Healthcare Co Pharmaceutical preparations containing Cabotgravir
KR102987126B1 (ko) * 2020-03-20 2026-07-07 길리애드 사이언시즈, 인코포레이티드 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법
CN116370479B (zh) * 2020-12-30 2024-02-13 南方科技大学 化合物atv014在制备用于治疗新冠病毒感染的产品中的用途
AU2022211056A1 (en) * 2021-01-25 2023-07-20 Brii Biosciences, Inc. Combination therapy for hiv with adenosine derivative and capsid inhibitors
KR20230132476A (ko) * 2021-01-25 2023-09-15 브리 바이오사이언시스, 인크. 아데노신 유도체 및 이를 포함하는 약제학적 조성물
WO2022182604A1 (en) * 2021-02-23 2022-09-01 Viiv Healthcare Company Compounds useful in hiv treatment
EP4658663A2 (en) * 2023-01-30 2025-12-10 Merck Sharp & Dohme LLC Prodrugs of 4'-substituted nucleoside reverse transcriptase inhibitors
US20250099464A1 (en) 2023-09-27 2025-03-27 ViiV Healthcare UK (No.3) Limited Pharmaceutical compositions
AU2023466962A1 (en) 2023-09-27 2026-03-12 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DE60005502T2 (de) 1999-05-12 2004-06-24 Yamasa Corp., Choshi 4'-c-ethynyl-purin-nukleoside
WO2002074769A1 (en) 2001-03-19 2002-09-26 Ono Pharmaceutical Co., Ltd. Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient
US7037718B2 (en) 2001-10-26 2006-05-02 Cornell Research Foundation, Inc. Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
CN100532388C (zh) 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
US8927513B2 (en) 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
US9198972B2 (en) 2010-01-28 2015-12-01 Alnylam Pharmaceuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
AU2011305652B2 (en) 2010-09-22 2016-10-20 Janssen Biopharma, Inc. Azido nucleosides and nucleotide analogs
UY34372A (es) 2011-10-06 2013-05-31 Dow Agrosciences Llc Moléculas de ácido nucleico que se dirigen a rpa70 y confieren resistencia a plagas de coleópteros.
KR102072041B1 (ko) 2011-12-22 2020-01-31 앨리오스 바이오파마 인크. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그의 유사체
SI2827875T1 (sl) 2012-03-21 2019-04-30 Alios Biopharma, Inc. Substituirani nukleozidi, nukleotidi in njihovi analogi
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
ES2952714T3 (es) 2013-06-26 2023-11-03 Janssen Pharmaceuticals Inc Nucleósidos sustituidos, nucleótidos y análogos de los mismos
CN105829333A (zh) 2013-10-11 2016-08-03 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸及其类似物
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
US9603864B2 (en) 2014-06-24 2017-03-28 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
SG11201610597QA (en) 2014-06-24 2017-01-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
WO2016057866A1 (en) 2014-10-09 2016-04-14 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
CN107074899A (zh) * 2014-10-31 2017-08-18 桑多斯股份公司 改进的氟化工艺
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
JP6768796B2 (ja) * 2015-09-23 2020-10-14 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 4’−置換ヌクレオシド逆転写酵素阻害剤及びその調製
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
JP7160466B2 (ja) 2016-06-23 2022-10-25 ヴィーブ ヘルスケア カンパニー 治療薬の送達のための組成物及び方法
WO2018085307A1 (en) 2016-11-03 2018-05-11 Wu Laurence I Prodrugs of clofarabine
US20190185508A1 (en) 2017-12-15 2019-06-20 Merck Sharp & Dohme Corp. Deuterated nucleoside reverse transcriptase inhibitors
WO2019171285A1 (en) * 2018-03-07 2019-09-12 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
CA3096400A1 (en) 2018-04-09 2019-10-17 Eisai R&D Management Co., Ltd. Certain pladienolide compounds and methods of use
MA53280A (fr) 2018-08-09 2021-11-17 Glaxosmithkline Ip No 2 Ltd Composés utiles dans la thérapie du vih
US20210323993A1 (en) 2018-08-30 2021-10-21 Glaxosmithkline Intellectual Property (No. 2) Limited Compounds Useful in HIV Therapy
US12018435B2 (en) 2019-03-06 2024-06-25 Chemstone, Inc. Liquid dispersions for acyl halides

Similar Documents

Publication Publication Date Title
JP2024516371A5 (cg-RX-API-DMAC7.html)
JP2010530376A5 (cg-RX-API-DMAC7.html)
JP2024540183A5 (cg-RX-API-DMAC7.html)
RU2013121788A (ru) Ингибиторы репликации вич
JP2016530259A5 (cg-RX-API-DMAC7.html)
JP2018021046A5 (cg-RX-API-DMAC7.html)
AR067184A1 (es) Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica
HRP20211543T1 (hr) Derivati kinazolina koji se koriste za liječenje hiv-a
JP2016508134A5 (cg-RX-API-DMAC7.html)
JP2022537047A5 (cg-RX-API-DMAC7.html)
RU2015131006A (ru) ЗАМЕЩЕННОЕ ПРОИЗВОДНОЕ СПИРОПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В МЕДИЦИНЕ В КАЧЕСТВЕ ИНГИБИТОРА ИНТЕГРАЗЫ ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА (ВИЧ)
JP2009535352A5 (cg-RX-API-DMAC7.html)
JP2020505423A5 (cg-RX-API-DMAC7.html)
JP2015038149A5 (cg-RX-API-DMAC7.html)
JP2013519675A5 (cg-RX-API-DMAC7.html)
JP2022505597A5 (cg-RX-API-DMAC7.html)
RU2011127080A (ru) Производное циклоспорина для применения в лечении заражения вирусом гепатита с и вич
JP2021521118A5 (cg-RX-API-DMAC7.html)
JP2022531251A5 (cg-RX-API-DMAC7.html)
JP2017529830A5 (cg-RX-API-DMAC7.html)
JP2020529995A5 (cg-RX-API-DMAC7.html)
RU2019112148A (ru) Фармацевтическая композиция и способ лечения неалкогольной жировой болезни печени
JP2014148552A5 (cg-RX-API-DMAC7.html)
FI3506900T3 (fi) Ampreloksetiini käytettäväksi neurogeenisen ortostaattisen hypotension
FI3528791T3 (fi) Dispergoituvia koostumuksia